

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JW (Cayman) Therapeutics Co. Ltd

藥明巨諾（開曼）有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2126)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON JANUARY 17, 2023

Reference is made to the circular of JW (Cayman) Therapeutics Co. Ltd (the “**Company**”) dated December 30, 2022 (the “**Circular**”) incorporating, amongst others, the notice (the “**Notice**”) of extraordinary general meeting of the Company (the “**EGM**”). Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

At the EGM held on January 17, 2023, the proposed ordinary resolution as set out in the Notice was taken by poll.

As at the date of the EGM, the total number of issued Shares was 411,061,070 Shares, which was the total number of Shares entitling the holders to attend and vote for or against the resolution proposed at the EGM.

Pursuant to the Listing Rules and as stated in the Circular, Juno and its associates (who, as far as the Directors were aware, is holding an aggregate of 70,231,140 Shares, representing approximately 17.09% of the total issued share capital of the Company as of the date of the EGM) were required to abstain from voting on the resolution at the EGM. As such, the total number of Shares entitling the Independent Shareholders to attend and vote on the resolution proposed at the EGM was 340,829,930 Shares. Save as disclosed above, there was no restriction on any Shareholder casting votes on the proposed resolution at the EGM. There was no Share entitling the Shareholders to attend and vote only against the proposed resolution at the EGM. No party has stated its intention in the Circular that it would vote against any proposed resolution or that it would abstain from voting at the EGM.

The Company's Hong Kong share registrar, Computershare Hong Kong Investor Services Limited was appointed as the scrutineer at the EGM for the purpose of vote-taking. The poll results in respect of the resolution proposed at the EGM were as follows:

ORDINARY RESOLUTION	Number of votes cast and approximate percentage of total number of votes cast	
	For	Against
To hereby approve, ratify and confirm the License and Collaboration Agreement and its execution thereof and implementation of the transactions contemplated thereunder, and to authorize any Director or any other person authorized by the Directors, to sign, execute, perfect and deliver all such documents, instruments and agreements and do all such deeds, acts, matters and things as they consider necessary, desirable or expedient to carry out or give effect to or otherwise in connection with the License and Collaboration Agreement and the transactions contemplated thereunder.	61,357,544 100%	0 0%

The Board consists of eight Directors, four of whom attended the EGM by way of electronic means. Ms. Xing Gao, Mr. Jinyin Wang, Dr. Cheng Liu and Mr. Yiu Leung Andy Cheung did not attend the EGM due to other work arrangements.

Please refer to the Notice for the full text of the resolution.

As more than 50% of votes were cast in favour of the above resolution, the ordinary resolution was duly passed at the EGM.

By order of the Board
JW (Cayman) Therapeutics Co. Ltd
 藥明巨諾（開曼）有限公司*
Yiping James Li
Chairman

Shanghai, PRC, January 17, 2023

As at the date of this announcement, the Board comprises Dr. Yiping James Li as Chairman and executive Director; Dr. Krishnan Viswanadhan, Ms. Xing Gao, Dr. Ann Li Lee, Mr. Jinyin Wang, Dr. Cheng Liu as non-executive Directors, and Mr. Yiu Leung Andy Cheung, Mr. Kin Cheong Kelvin Ho as independent non-executive Directors.

* For identification purpose only